Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
National Hospital Week: Always Here for Our Patients and Communities
National Hospital Week, observed May 10‑16, spotlights the indispensable role of hospitals and their staff in American communities. The American Hospital Association (AHA) is distributing social‑media toolkits, infographics, and advisory resources to help health systems recognize caregivers during the week. The campaign underscores hospitals as major employers, community health partners, and emergency responders. It also calls for sustained investment in the healthcare workforce to maintain resilience beyond the celebration.
'Pharma, Not Really’: Top Young AI Talent Shuns Careers at Big Drugmakers
Top AI researchers like 33‑year‑old postdoctoral fellow Mazdak Abulnaga are increasingly turning away from legacy pharmaceutical companies. The article highlights a growing perception that big drugmakers are bureaucratic, data‑restricted, and slow to adopt cutting‑edge machine‑learning tools. In contrast, startups, academia,...
How States Can Succeed Under the Rural Health Transformation Program
States have received their first‑year Rural Health Transformation Program (RHTP) grants, with allocations ranging from $147 million in New Jersey to $281 million in Texas, covering all 50 states. The funding arrives amid a rural health crisis, where 200 hospitals have closed since...
Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention
The U.S. Food and Drug Administration has issued a final Level 1 guidance titled “Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention.” The document replaces the October 2022 draft and provides detailed recommendations for clinical trial design, endpoints,...
Pulmonary Tuberculosis: Developing Drugs for Treatment
The FDA has issued a final Level 1 guidance titled “Pulmonary Tuberculosis: Developing Drugs for Treatment,” replacing the draft released in December 2022. The guidance, docket FDA‑2013‑D‑1319, outlines clinical development expectations for new antibacterial agents targeting pulmonary TB. It provides sponsors with detailed...
The Peptide Split: How GLP-1s, Lutathera, Vosoritide, and Peptide Cancer Vaccines Are Quietly Rewriting Medicine While BPC-157, TB-500, MOTS-C, and...
Peptide therapeutics are diverging into two distinct trajectories. Clinically validated drugs such as GLP‑1 agonists, Lu‑177 radioligands, vosoritide, and emerging peptide cancer vaccines are delivering hard‑outcome data across cardiometabolic disease, oncology and rare disorders. In parallel, a booming wellness market...
Postapproval Pregnancy Safety Studies
The FDA has released its final Level 1 guidance on post‑approval pregnancy safety studies, updating the 2019 draft to provide detailed recommendations for designing investigations of drug and biologic exposure in pregnant women. The guidance outlines methodological standards, data sources, and...
Mobia Medical Prices $150 Million IPO to Fund Stroke‑Device Platform
Mobia Medical, Inc. priced a 10 million‑share public offering at $15 per share, raising roughly $150 million. The Nasdaq‑listed ticker “MOBI” will debut on May 8, giving the stroke‑device firm capital to accelerate product development and market rollout.
A New Approach to Treating Recurrent Urinary Tract Infections
Urologist Jitesh Patel outlines a non‑antibiotic protocol for recurrent urinary tract infections, emphasizing symptom‑driven diagnosis, aggressive bladder hygiene, and targeted adjuncts such as Hiprex, vaginal estrogen, and metabolic optimization. He argues that reflex antibiotic prescribing has created a cohort of...
Over 3,000 Attacks on Ukraine Healthcare Since Start of War: WHO
The World Health Organization reported more than 3,000 confirmed attacks on Ukraine’s healthcare facilities since Russia’s full‑scale invasion began in February 2022. Over 1,534 days of fighting, 80% of strikes hit outpatient clinics, hospitals and other care sites, while ambulances accounted...
New Special Issue of TMRB
The IEEE Transactions on Medical Robotics and Bionics (T‑MRB) has issued a special edition tied to the 13th CRAS conference and the upcoming ICORR 2025, spotlighting the latest surgical‑robotics research presented in Odense, Denmark. The in‑person CRAS 2024 event featured...
Why some Brain Cells Are Particularly Vulnerable to Multiple Sclerosis
Researchers identified that CUX2 cortical neurons, essential for higher cognition, are uniquely vulnerable in progressive multiple sclerosis due to accumulated DNA damage. The protein ATF4 initiates a DNA‑repair kit that safeguards these cells; disabling ATF4 in mice triggers rapid CUX2...
Heart, Kidney, Metabolic Issues Raise Cancer Risk 30%
Heart, Kidney, Metabolic Disease Linked to 30% Higher Cancer Risk As a medical school professor, I teach cardiovascular and cancer medicine as separate silos. A new study of 1.4 million adults says we have to stop. Circulation: Population Health and Outcomes, April...
Biotech Layoffs Are Easing, but Is the Worst Over?
Biotech layoffs are decelerating in 2026, with 40 rounds announced by April 30 versus more than 50 in the final months of 2025. The slowdown follows a 16 % year‑over‑year rise in cuts driven by drug failures, strategic pivots and cost pressures...
People with Premenstrual Dysphoric Disorder Have Higher Rates of Suicidal Thinking, Planning and Attempts
A systematic review of 18 studies covering over 2 million menstruating individuals found that people with premenstrual dysphoric disorder (PMDD) experience markedly higher rates of suicidal thoughts, planning, and attempts than those without the condition. Reported prevalence varied widely, from 0.011 %...
Chinese Health Authority Says No Need to Worry About Latest Hantavirus Outbreak
China’s Centre for Disease Control and Prevention announced that no human infections have been recorded from the Andes‑origin hantavirus linked to the recent outbreak on the Dutch cruise ship MV Hondius. The virus, primarily carried by rodents, rarely spreads between...
Why More Texas Small Businesses Are Switching From Group Plans to Association Plans
Texas small businesses are grappling with traditional group health insurance that averages $7,000‑$9,000 per employee annually, making coverage for a 10‑person team comparable to a full marketing budget. To curb these costs, many are turning to association health plans (AHPs),...
What Is PDUFA—And Why Does It Matter for Biotech Innovators, FDA & Patients?
Congress will reauthorize the Prescription Drug User Fee Act (PDUFA) next year, renewing the FDA’s authority to collect fees from biotech firms for drug reviews. The user‑fee model supplies a stable budget that underpins faster, more predictable approval timelines—about ten...
The US FDA Grants IND Clearance to Harbour BioMed’s HBM7004 to Initiate P-I Trial in Advanced Solid Tumors
The U.S. Food and Drug Administration has granted IND clearance for Harbour BioMed’s bispecific antibody HBM7004, allowing a Phase I trial in patients with advanced solid tumors. HBM7004 links the tumor‑associated antigen B7H4 to CD3, redirecting T‑cells to the tumor...
Friday Hope: Eriodictyol: Found in Citrus Fruits, This Flavonoid Downregulates ACE2, TMPRSS2 and TGF-Β
The post highlights eriodictyol, a citrus‑derived flavanone, as a multi‑target therapeutic candidate. Recent studies show it can down‑regulate ACE2 and TMPRSS2, the key entry proteins for SARS‑CoV‑2, and suppress TGF‑β‑driven fibrosis in animal models. Additional research links eriodictyol to neuroprotective...
Eisai, Biogen Face Delay to Subcutaneous Leqembi
The FDA has extended its review of Eisai and Biogen’s subcutaneous Leqembi Iqlik, moving the decision on its use as a starting dose to August 24. The agency requested a major amendment to the marketing application but has not raised safety...
PopInfo Weekly: Leaks, Lapses, and Lies
A recent PopInfo Weekly roundup highlights several accountability lapses across the U.S. government and private sector. The Trump administration has not paid ICE detainee medical bills for over seven months, coinciding with a spike in deaths, while Popular Information estimates...
Morning Digest: How Oklahoma Democrats Just Helped Sabotage a GOP Plan to Roll Back Medicaid Expansion
Oklahoma Democrats, joined by a handful of Freedom Caucus Republicans, blocked a GOP‑backed emergency clause that would have moved a Medicaid‑expansion repeal vote to the August primary runoff. The GOP now proposes a single November referendum that would strip the...
FRIDAY EDITION: Dawn Dispatch // May 8th
The author’s Friday newsletter highlights two recent pieces: a deep‑dive into a 150‑year‑old law that could reshape Supreme Court rulings on the abortion pill, and a kid‑focused historical article on Great Depression‑era penny restaurants. Both pieces are linked for readers,...
Is This the Next Pandemic? The Hantavirus Headlines Explained
The blog post breaks down hantavirus for a nervous public, explaining that it is a rodent‑borne virus transmitted through inhaled droppings rather than person‑to‑person contact. It highlights the global burden—over 150,000 cases a year, with only 20‑50 annual infections in...
Gilead Sets Blockbuster Bar for Yeztugo’s First Full Year on the Market
Gilead announced a $1 billion sales target for its twice‑yearly PrEP injection Yeztugo in 2026, up from a prior $800 million outlook. The drug generated $166 million in Q1, a 72% increase from the previous quarter, and 95% of U.S. patients enjoy $0...
Doctors Must Google Themselves to Avoid Misidentification
Tag a physician who has never Googled their own name. They need to. Dr. Stephanie Waggel did, and the top result wasn’t her. It was a large corporate clinic she has no affiliation with. Save this before the next time...
In-Home Personal Care Services for Everyday Support
In‑home personal care services provide tailored assistance with daily activities such as bathing, dressing, mobility, and medication reminders, enabling seniors and recovering patients to stay safely at home. Care plans are customized, ranging from a few weekly visits to round‑the‑clock...
Home Tonometers: A Guide to Safe and Simple IOP Checks
Home tonometers let patients with glaucoma or other intraocular pressure (IOP) conditions measure eye pressure at home, reducing the need for frequent clinic visits. These portable devices use either gentle contact or a brief puff of air to deliver digital...
FDA Clears Flow Neuroscience’s At‑Home Brain‑Stimulation Headset for Depression
The U.S. Food and Drug Administration approved Flow Neuroscience’s FL-100 at‑home transcranial direct current stimulation headset for adults with major depressive disorder, marking the first regulatory clearance for a consumer‑grade neurostimulation device. The decision opens a non‑drug, clinic‑free treatment pathway...
Voluntary Certification Becomes Unavoidable Gatekeeper in Medicine
A classic episode, republished in memory of Dr. Manny Konstantakos, an orthopedic surgeon and longtime advocate for physician choice in board certification, who passed away suddenly in 2023. Maintenance of Certification is voluntary. Hospitals will not credential you without it. Insurers...
GLP‑1 Breakthrough Costs $500/Month, Limiting Access
After catching my breath (unusual for GLP-1 story to discuss their costs approvingly), I suspect both that @continetti (not unusually) is likely directionally right (& I share enthusiasm for free market) - but - at $500/mo for transformative drug -...
WHO Blunder Imperils Remaining Passengers on Hantavirus-Infected Cruise Ship
In this episode, host Steve discusses a hantavirus outbreak aboard a cruise ship off the coast of Cape Verde, where passengers are confined to cabins while the virus spreads via rodent droppings and recirculated air. Dr. Peter McCullough, chief scientific officer...
Compassion, Not Tech, Defines Top Cardiology Care
My dear 92yo mother-in-law did not survive her heart attack. The CCU team showed our family what cardiology at its best looks like, and it wasn't the technology. My @JACCJournals Editor's Page on the experience: https://t.co/RzhvSMOm8R https://t.co/nFTQmR06sK
Episode 400: Daphne Zohar on Seaport’s IPO Success
On this week’s Readout LOUD podcast, @daphnezohar was our very special guest. We chatted about Seaport and its successful IPO. Also, this week is Episode No. 400! https://t.co/5o02LIjjD6
3 Things AI in Health Care Investing Cannot Evaluate
Physician‑scientist Harsha Moole built an AI system that rapidly compiles data and scores healthcare startups, dramatically speeding the information‑gathering phase of venture diligence. He stresses that despite its efficiency, the AI cannot replace human judgment when evaluating clinical workflow integration, stakeholder...
Natalie Holles' Next Move After Third Harmonic Shutdown; Mark Alles Passes the Torch at ADC Biotech
Natalie Holles rebounded quickly after the shutdown of Third Harmonic, securing the chief executive role at Aura Biosciences. The transition was disclosed in a GlobeNewswire release on May 4, 2026, as the company moves toward enrollment completion for its Phase‑3 COMPASS trial....
Capricor Sues Nippon Shinyaku over Duchenne Drug 'Pricing Flaw' And Launch Prep
Capricorn Therapeutics has filed a lawsuit against Japan’s Nippon Shinyaku, alleging a breach of their licensing agreement for the Duchenne muscular dystrophy cell‑therapy candidate deramio‑cel. The complaint centers on a pricing flaw that Capricorn says Nippon Shinyaku misrepresented during launch...
AI-Enabled Care: Transforming Safety and Independence for Vulnerable Adults
The UK’s ageing population and 15 million mobility‑limited adults are straining health and social services, prompting a shift toward AI‑enabled home care. Predictive algorithms can analyze activity, medication adherence, and sleep patterns to flag risks before crises emerge, potentially cutting emergency...
Added Sugar Labels Would Prompt Teens to Dump Sugary Drinks, Research Shows
A new SAHMRI study published in BMC Nutrition shows that front‑of‑pack warning labels displaying the number of teaspoons of added sugar on sugary drinks can dramatically shift teenage behavior, with many opting to stop buying or drinking them. Australian adolescents...
John Stockton Blocked by U.S. Supreme Court in COVID Speech Case
The U.S. Supreme Court denied former NBA star John Stockton’s petition to review a First Amendment challenge against Washington state officials who investigated doctors for “dangerous” COVID‑19 viewpoints. Lower courts had dismissed the case, invoking the Younger Doctrine and finding...
Endometriosis Imaging Study Highlights 99mTc-Maraciclatide as Diagnostic and Monitoring Tool
Serac Healthcare and Oxford’s Nuffield Department have published Phase 2 results of the DETECT study, showing that the gamma‑emitting radiotracer 99mTc‑maraciclatide can non‑invasively locate endometriotic lesions, including superficial peritoneal disease. Imaging findings matched laparoscopy in 16 of 19 participants and identified disease...
J&J Seeks to Rewrite the Script on Depression Treatment
Johnson & Johnson’s new Generation Fine survey of 859 patients and 800 clinicians across eight countries found that nearly four‑in‑five people with major depressive disorder doubt oral antidepressants will fully resolve their symptoms. Residual symptoms linger for about 75% of...
AI‑enhanced Dog Breath Test Detects Cancers with 90%+ Accuracy
New MCED / cancer screening test: Dogs smell human breathing + Bayesian AI detects multiple cancers with 90.8% sensitivity & 91.3% specificity (AUC 0.962), even in early stages. Phase II India study (1,502 people, 7 cancer types)- strong potential for affordable...
Canvys Expands 4K Display Platform for Medical Applications with New 32-Inch Monitor
Canvys, a division of Richardson Electronics, has added a 32‑inch 4K monitor to its medical‑grade display platform, extending the existing 27‑inch offering. The new screen provides a larger viewing area, ultra‑high‑definition resolution and wide viewing angles for applications such as...
Legislature Writes Nurse-to-Patient Ratios Into Law, Adds Penalty Clause
Taiwan's Legislature has codified nurse‑to‑patient ratios into law, adopting the Ministry of Health and Welfare's 2024 targets and adding penalties for non‑compliance. Ratios start at 1:6 for day shifts in medical centers and scale up for regional and district hospitals....
FDA Reconsiders Ebvallo Cell Therapy After Surprise Rejection
Pierre Fabre Pharmaceuticals and Atara Biotherapeutics secured a meeting with the FDA that reversed the agency’s Jan. 2026 rejection of their EBV‑associated T‑cell therapy, Ebvallo. The regulator now deems the completed single‑arm trial sufficient for a resubmission, opening a path...
Bausch + Lomb Launches Bi-Blade+ Vitrectomy Cutter in the EU on Stellaris Elite Platform
Bausch + Lomb has introduced the Bi‑Blade+ dual‑port vitrectomy cutter on its Stellaris Elite Vision Enhancement System across the European Union. The new cutter delivers a 25% higher vitreous flow rate than the original Bi‑Blade, while cutting cutter vibration by 62%, which...
Samsung Galaxy Watch6 Can Predict Fainting 5 Minutes Early, Study Shows
Samsung announced that its Galaxy Watch6 can warn users of an impending fainting episode up to five minutes in advance, achieving 84.6% accuracy in a clinical trial of 132 participants. The feature relies on the watch’s PPG sensor and AI‑driven...
StuffThatWorks Appoints Caroline Redeker as Chief Commercial Officer
StuffThatWorks announced Caroline Redeker as chief commercial officer, adding more than 30 years of CRO leadership to its team. The company’s AI‑native platform already connects over three million patients, delivering 1.3 billion structured data points for drug development and commercialization. Redeker...